Highlights

  • 1

    The impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC).

  • 2

    Which genomic assays provide guidance in patients with HR+, HER2-, node-negative breast cancer.

  • 3

    How the use of biomarkers may guide decisions on adjuvant systemic therapy in women with early-stage invasive breast cancer.

  • 4

    How the Breast Cancer Index (BCI) can be used for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated with the adjuvant tamoxifen.

  • 5

    HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab.

  • 6

    How immunophenotype and proliferation may help predict response to neoadjuvant chemotherapy in TNBC.

  • 7

    How genomic markers may help predict early and emergent resistance in ER+ metastatic breast cancer (MBC).

Summary

The impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC). TAILORx and Clinical Risk: Main Results are presented and implications are discussed. Which genomic assays provide guidance in patients with HR+, HER2-, node-negative breast cancer. How the use of biomarkers may guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. Based on Oncotype DX recurrence score and age what are the recommendations for hormone receptor positive, HER2 not overexpressed, axillary node negative breast cancer.

Based on the Trans-aTTom study data, how the Breast Cancer Index can be used for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen.

Looking at the HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab.

From the Results from BrighTNess study, how immunophenotype and proliferation may help predict response to neoadjuvant chemotherapy in TNBC.

From the Biomarker analysis of the APHINITY trial how Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC)

How genomic markers may help predict early and emergent resistance. A review of a large retrospective analysis of CDK 4/6-inhibitor retreatment in ER+ metastatic breast cancer (MBC). From the PALOMA-3 trial the importance of Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer.

This event is sponsored by: :

Interviewee

User

Vered Stearns, M.D.

Professor of Oncology, Co-Director, Breast an ...
at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Under Armour Breast Health Innovation Center The Skip Viragh Outpatient Cancer Building

Baltimore, MD, USA

Dr. Stearns co-leads the Breast and Ovarian Cancer Program at the Johns Hopkins Kimmel Cancer Center. She is the associate director for oncology...

User

Antoine Abugaber

Niagara Falls, Ontario

While in the Medical Department in large Pharma he held the positions of; Director of Clinical Operations, International Clinical Research and Develop...

Comments (0)